World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
78
Citations
24346
World Ranking
17981
National Ranking
8963

Douglas S. Goodin publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Douglas S. Goodin sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 266 publications — 10th percentile

10% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Douglas S. Goodin D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Douglas S. Goodin sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 78 D-Index — 12th percentile

12% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Douglas S. Goodin is affiliated with the University of California, San Francisco in the United States. Their research primarily centers on the field of medicine, with a focus on pathology and forensic medicine, neurology, immunology, rheumatology, and radiology, nuclear medicine, and imaging.

The scientist's work addresses major topics related to multiple sclerosis research studies, T-cell and retrovirus studies, neuroinflammation and neurodegeneration mechanisms, systemic lupus erythematosus research, advanced neuroimaging techniques and applications, long-term effects of COVID-19, and peripheral neuropathies and disorders.

Douglas S. Goodin has contributed to several peer-reviewed research papers. Notable recent publications include:

  • Synaptic injury in the inner plexiform layer of the retina is associated with progression in multiple sclerosis, 2024, Cell Reports Medicine
  • Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis, 2021, Annals of Neurology
  • The nature of genetic and environmental susceptibility to multiple sclerosis, 2021, PLoS ONE
  • Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS, 2020, American Journal of Neuroradiology
  • An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis, 2020, Multiple Sclerosis Journal

Douglas S. Goodin frequently collaborates with other researchers in the field. Common coauthors include Riley Bove, Bruce Cree, Stephen L. Hauser, Refujia Gomez, and Jeffrey M. Gelfand.

The scientist's publications are often found in prominent venues related to neurology and medicine, including Annals of Neurology, PLoS ONE, American Journal of Neuroradiology, Cell Reports Medicine, and Journal of Neurology Neurosurgery & Psychiatry.

Best Publications

  • Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.

    D. S. Goodin;Elliot Frohman;G. P. Garmany;J. Halper

  • Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

    Peter A. Calabresi;Ernst Wilhelm Radue;Douglas Goodin;Douglas Jeffery

  • Age-related variations in evoked potentials to auditory stimuli in normal human subjects

    Douglas S Goodin;Kenneth C Squires;Beverley H Henderson;Arnold Starr

  • Assessment: Transcranial Doppler ultrasonography: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

    M. A. Sloan;M. A. Sloan;Andrei Alexandrov;C. H. Tegeler;M. P. Spencer

  • Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.

    Hillel Panitch;D. S. Goodin;G. Francis;P. Chang

  • Long latency event-related components of the auditory evoked potential in dementia

    Douglas S. Goodin;Kenneth C. Squires;Arnold Starr

  • INCIDENTAL MRI ANOMALIES SUGGESTIVE OF MULTIPLE SCLEROSIS: THE RADIOLOGICALLY ISOLATED SYNDROME

    Darin Okuda;E. M. Mowry;A. Beheshtian;E. Waubant

  • Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis

    Sergio E. Baranzini;Joanne Wang;Rachel A. Gibson;Nicholas Galwey

  • 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

    Paul O'Connor;Massimo Filippi;Barry Arnason;Giancarlo Comi

  • Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial

    Jerry S. Wolinsky;Ponnada A. Narayana;Paul O'Connor;Patricia K. Coyle

  • Silent progression in disease activity-free relapsing multiple sclerosis.

    Bruce A C Cree;Jill A Hollenbach;Riley Bove

  • Assessment: Prevention of post-lumbar puncture headaches: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

    Randolph W. Evans;Randolph W. Evans;Carmel Armon;Elliot M. Frohman;Douglas S. Goodin

  • Mapping Multiple Sclerosis Susceptibility to the HLA-DR Locus in African Americans

    Jorge R. Oksenberg;Lisa F. Barcellos;Bruce A.C. Cree;Sergio E. Baranzini

  • HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course

    L.F. Barcellos;J.R. Oksenberg;A.B. Begovich;E.R. Martin

  • Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis

    B. A.C. Cree;O. Khan;D. Bourdette;D. S. Goodin

  • Clinical utility of surface EMG Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

    S.L. Pullman;D.S. Goodin;A.I. Marquinez;S. Tabbal

  • Survival in MS A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial

    D.S. Goodin;A.T. Reder;G.C. Ebers;G. Cutter

  • Mortality in patients with multiple sclerosis

    Antonio Scalfari;Volker Knappertz;Gary Cutter;Douglas S. Goodin

  • Electrophysiological differences between subtypes of dementia.

    Douglas S. Goodin;Michael J. Aminoff

  • IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.

    Douglas S. Goodin

Frequent Co-Authors

Michael J. Aminoff
Michael J. Aminoff University of California, San Francisco
Anthony T. Reder
Anthony T. Reder University of Chicago
Bruce A. C. Cree
Bruce A. C. Cree University of California, San Francisco
Stephen L. Hauser
Stephen L. Hauser University of California, San Francisco
George C. Ebers
George C. Ebers University of Oxford
Barry G. W. Arnason
Barry G. W. Arnason University of Chicago
Ludwig Kappos
Ludwig Kappos University Hospital of Basel
Gary Cutter
Gary Cutter University of Alabama at Birmingham
Emmanuelle Waubant
Emmanuelle Waubant University of California, San Francisco
Massimo Filippi
Massimo Filippi Vita-Salute San Raffaele University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in medicine but want flexible study options, several online degree pathways may align with your goals. For registered nurses, adn to fnp bridge programs allow you to advance quickly into family nurse practitioner roles without starting from scratch. Current RNs can also enroll in an rn to bsn online without clinicals pathway, ideal for those seeking advancement while balancing work and home life.

Beyond nursing, there is growing demand for preventive care and wellness expertise. Earning a nutrition degrees online qualification can prepare you for roles in community health, dietetics, and wellness coaching. For those interested in healthcare leadership, whats the best online mha program for working adults covers how to lead hospitals and health organizations without interrupting your current career.

These diverse options reflect the evolving landscape of medical education, making it easier to upskill or transition into rewarding roles in healthcare—entirely online.

Best Scientists Citing Douglas S. Goodin

Trending Scientists

Recently Published Articles